There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytosorbents Corp (CTSO) and Rexahn Pharma (RNN) with bullish sentiments.
Cytosorbents Corp (CTSO)
In a report released yesterday, Andrew D’silva from B.Riley FBR maintained a Buy rating on Cytosorbents Corp, with a price target of $13.50. The company’s shares opened today at $7.23, close to its 52-week low of $6.60.
“Earlier this month, CytoSorbents Corporation (CTSO) provided an update on the progress it made in 2018 and expected future milestones. We were also recently able to meet with the company’s management in San Francisco. Consolidated sales for 4Q18 are expected to come in at ~$5.9M, with product sales of ~$5.4M. We were looking for consolidated and product sales of $6.6M and $6.2M, respectively. We believe the miss was likely due to CTSO running into a bottleneck from high utilization of its direct sales/marketing infrastructure, which is primarily focused on Germany, as well as from a slower than expected uptick in distributor/ strategic partner sales.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 8.1% and a 37.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., EyePoint Pharmaceuticals Inc, and Imprimis Pharmaceuticals.
Currently, the analyst consensus on Cytosorbents Corp is a Strong Buy with an average price target of $16.50, a 128.2% upside from current levels. In a report issued on January 14, H.C. Wainwright also maintained a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
Rexahn Pharma (RNN)
In a report released yesterday, George Zavoico from B.Riley FBR maintained a Buy rating on Rexahn Pharma, with a price target of $7.50. The company’s shares opened today at $0.61, close to its 52-week low of $0.55.
“18, clinical investigators from six trial sites in the U.S. presented updated positive interim safety and efficacy data from an ongoing Phase IIa clinical trial of RX-3117 in combination with nab-paclitaxel (Abraxane) as front-line therapy in patients with metastatic pancreatic cancer at the 2019 Gastrointestinal (ASCO- Francisco, California. RX-3117 is Rexahn Pharmaceuticals, Inc.’s (RNN) leading drug candidate and a prodrug of a nucleoside analog activated by an enzyme highly expressed in tumors and largely absent in healthy cells. The 38% overall response rate (ORR) in 24 evaluable patients (so far) exceeds the 23% ORR reported for gemcitabine in combination with Abraxane in Abraxane’s product label.”
According to TipRanks.com, Zavoico has 0 stars on 0-5 star ranking scale with an average return of -10.0% and a 33.7% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Cellular Biomedicine Group, and Miragen Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rexahn Pharma with a $13.50 average price target, implying a 2113.1% upside from current levels. In a report issued on January 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $17 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RNN: